Monoclonal antibodies that specifically bind to and neutralize
View Patent ↗The invention features compositions relating to antibodies that specifically bind to the protective antigen of Bacillus anthracis , fragments thereof, and nucleic acids encoding same. The invention further features methods of using such compositions.
1. An isolated antibody, or antigen binding fragment thereof, comprising:
a heavy chain polypeptide comprising contiguous amino acid sequences of complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3 of a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 13;
and a light chain polypeptide comprising contiguous amino acid sequences of a CDRL1, a CDRL2; and
a CDRL3 of a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 17, wherein the antibody, or antigen binding fragment thereof binds to protective antigen (PA).
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated antibody, or antigen binding fragment thereof, of claim 1 .
3. A library of antibodies comprising the antibody, or antigen binding fragment thereof, of claim 1 and at least one antibody selected from the group consisting of 4A12, 24B1, 24G4, 32E12, and 33F4.
4. A method of producing a polypeptide, the method comprising:
culturing a host cell comprising a nucleic acid encoding the antibody, or antigen binding fragment thereof, according to claim 1 under conditions to provide for polypeptide expression.
5. An isolated antibody, or an antigen binding fragment thereof, comprising:
a heavy chain polypeptide comprising contiguous amino acid sequences of the complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3 of a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 21; and
a light chain polypeptide comprising contiguous amino acid sequences of a CDRL1, a CDRL2, and a CDRL3 of a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 25, wherein the antibody, or antigen binding fragment thereof binds to protective antigen (PA).
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated antibody, or antigen binding fragment thereof, of claim 5 .
7. A library of antibodies comprising the antibody, or antigen binding fragment thereof of claim 5 and at least one antibody selected from the group consisting of 1A5, 24B1, 24G4, 32E12, and 33F4.
8. An isolated antibody, or an antigen binding fragment thereof, comprising:
a heavy chain polypeptide comprising contiguous amino acid sequences of the complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3 of a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 29; and
a light chain polypeptide comprising contiguous amino acid sequences of a CDRL1, a CDRL2, and a CDRL3 of a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 33, wherein the antibody, or antigen binding fragment thereof binds to protective antigen (PA).
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated antibody, or antigen binding fragment thereof, of claim 8 .
10. A library of antibodies comprising the antibody, or antigen binding fragment thereof of claim 8 and at least one antibody selected from the group consisting of 1A5, 4A12, 24G4, 32E12, and 33F4.
11. An isolated antibody, or an antigen binding fragment thereof, comprising:
a heavy chain polypeptide comprising contiguous amino acid sequences of the complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3 of a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 37; and
a light chain polypeptide comprising contiguous amino acid sequences of a CDRL1, a CDRL2, and a CDRL3 of a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 41, wherein the antibody, or antigen binding fragment thereof binds to protective antigen (PA).
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated antibody, or antigen binding fragment thereof, of claim 11 .
13. A library of antibodies comprising the antibody, or antigen binding fragment thereof of claim 11 and at least one antibody selected from the group consisting of 1A5, 4A12, 24B1, 32E12, and 33F4.
14. An isolated antibody, or an antigen binding fragment thereof, comprising:
a heavy chain polypeptide comprising contiguous amino acid sequences of the complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3 of a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 45; and
a light chain polypeptide comprising contiguous amino acid sequences of a CDRL1, a CDRL2, and a CDRL3 of a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 49, wherein the antibody, or antigen binding fragment thereof binds to protective antigen (PA).
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated antibody, or antigen binding fragment thereof, of claim 14 .
16. A library of antibodies comprising the antibody, or antigen binding fragment thereof of claim 14 and at least one antibody selected from the group consisting of 1A5, 4A12, 24B1, 24G4, and 33F4.
17. An isolated antibody, or an antigen binding fragment thereof, comprising:
a heavy chain polypeptide comprising contiguous amino acid sequences of the complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3 of a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 53; and
a light chain polypeptide comprising contiguous amino acid sequences of a CDRL1, a CDRL2, and a CDRL3 of a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 57, wherein the antibody, or antigen binding fragment thereof binds to protective antigen (PA).
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the isolated antibody, or antigen binding fragment thereof, of claim 17 .
19. A library of antibodies comprising the antibody, or antigen binding fragment thereof of claim 17 and at least one antibody selected from the group consisting of 1A5, 4A12, 24B1, 24G4, and 32E12.
20. A method of producing a polypeptide, the method comprising:
culturing a host cell comprising a nucleic acid encoding the antibody, or antigen binding fragment thereof, according to claim 5 under conditions to provide for polypeptide expression.
21. A method of producing a polypeptide, the method comprising:
culturing a host cell comprising a nucleic acid encoding the antibody, or antigen binding fragment thereof, according to claim 8 under conditions to provide for polypeptide expression.
22. A method of producing a polypeptide, the method comprising:
culturing a host cell comprising a nucleic acid encoding the antibody, or antigen binding fragment thereof, according to claim 11 under conditions to provide for polypeptide expression.
23. A method of producing a polypeptide, the method comprising:
culturing a host cell comprising a nucleic acid encoding the antibody, or antigen binding fragment thereof, according to claim 14 under conditions to provide for polypeptide expression.
24. A method of producing a polypeptide, the method comprising:
culturing a host cell comprising a nucleic acid encoding the antibody, or antigen binding fragment thereof, according to claim 17 under conditions to provide for polypeptide expression.